Impact Biomedical (IBO) Share-based Compensation (2024 - 2026)

Impact Biomedical (IBO) has reported Share-based Compensation for 3 consecutive years, with $1.4 million the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 4865.52% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $1.4 million (up 2780.0% YoY), and the FY2025 full-year result was $190000.0, up 900.0% from the prior year.
• Share-based Compensation grew to $1.4 million in Q1 2026 per IBO's latest filing, from $2000.0 in the prior quarter.
• Across five years, Share-based Compensation topped out at $1.4 million in Q1 2026 and bottomed at $2000.0 in Q2 2025.
• Historically, Share-based Compensation has averaged $372500.0 across 3 years, with a median of $24000.0 in 2024.
• The widest YoY moves for Share-based Compensation: up 4865.52% in 2026, down 4865.52% in 2026.
• Over 3 years, Share-based Compensation stood at $19000.0 in 2024, then sank by 89.47% to $2000.0 in 2025, then soared by 71900.0% to $1.4 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.4 million, $2000.0, and $29000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.